Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status ≤2

Documented evidence of active multiple myeloma:

Newly diagnosed, not candidate for transplant
Relapsed/refractory who have received up to 3 prior lines of therapy

Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled:

Not refractory to prior Lenalidomide which is defined as no progression while receiving Lenalidomide or within 60 days of last dose of Lenalidomide
Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event (AE)

Exclusion Criteria:

Target Disease Exceptions

Plasma cell leukemia
Monoclonal gammopathy of undetermined significance (MGUS)
Smoldering Myeloma
Primary amyloidosis
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome